Article Text

Novel treatment (new drug/intervention; established drug/procedure in new situation)
A report of succinate dehydrogenase B deficiency associated with metastatic papillary renal cell carcinoma: successful treatment with the multi-targeted tyrosine kinase inhibitor sunitinib
  1. Mark Tuthill1,
  2. Ravi Barod2,
  3. Linda Pyle1,
  4. Terry Cook2,
  5. Shern Chew3,
  6. Martin Gore1,
  7. Patrick Maxwell2,
  8. Tim Eisen4
  1. 1
    Royal Marsden NHS Foundation Trust, Medical Oncology, London, SW3 6JJ, UK
  2. 2
    Imperial College London, Renal Section, London, W12 ONN, UK
  3. 3
    Willam Harvey Research Institute, Barts and The London, Queen Mary’s School of Medicine and Dentistry, London, EC1M 6BQ, UK
  4. 4
    Cambridge University, Cambridge, CB2 OQQ, UK
  1. marktuthill{at}


We report a patient who initially presented with an abdominal paraganglioma and subsequently metastatic papillary cell renal cancer. Genetic analysis revealed a 141 G>A (exon 2) Trp47X mutation within the succinate dehydrogenase B gene. Treatment with the novel multi-targeted tyrosine kinase inhibitor sunitinib resulted in a sustained partial response and reduced the level of the angiogenic marker PIGF.

Trial registration number: a6181037

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: Mark Tuthill, none to declare; Ravi Barod, none to declare; Linda Pyle, none to declare; Terry Cook, none to declare; Shern Chew, none to declare; Patrick Maxwell, ReOx Ltd: Director, consultant, equity holder; Martin Gore, Pfizer: honoraria, advisory board member, research support; Tim Eisen, Pfizer: honoraria, advisory board member, research support.

  • Patient consent: Patient/guardian consent was obtained for publication